100.00% -58.70

Mirati Therapeutics Inc (MRTX)

Mirati Therapeutics Inc (MRTX) 最新ニュース

Mirati Therapeutics Inc (MRTX)

Mirati Therapeutics Inc (MRTX) 最新ニュース

Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion - MSN

Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing - MSN

Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo New Zealand News

Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago - Yahoo Canada Shine On

Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo New Zealand News

Even after rising 4.0% this past week, Mirati Therapeutics (NASDAQ:MRTX) shareholders are still down 76% over the ... - Yahoo Canada Shine On

What You Need To Know About The Mirati Therapeutics, Inc. (NASDAQ:MRTX) Analyst Downgrade Today - Yahoo Movies UK

Citi upgrades Mirati to buy; cites valuation, leadership change - MSN

TOLREMO Welcomes Dr. Alan Sandler to Scientific Advisory Board - Yahoo Canada Finance

Broader KRAS inhibition methods include chaperoning, gluing, vaccinating - BioWorld Online

Merck puts KRAS cancer drug competitor to the test - Yahoo Finance

Bristol Myers Squibb to lay off hundreds of workers following its $4.8B merger with this San Diego biotech - The San Diego Union-Tribune

Bristol Myers says KRAS drug succeeds in key trial - Yahoo Finance

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and ... - Business Wire

Bristol Myers Squibb's Abecma recommended for EU approval - Pharmaceutical Technology

Billionaire Joe Lewis Nets 730% Gain on Stock Behind US Charges - Bloomberg

Tango Therapeutics: Making Its Way Into Clinic With 4 Cancer Drugs (NASDAQ:TNGX) - Seeking Alpha

Bristol Myers Squibb concludes Mirati acquisition for $5.8bn - Pharmaceutical Technology

Bristol Myers Squibb completes acquisition of Mirati Therapeutics, strengthening oncology portfolio - ROI-NJ.com

2023's top 10 clinical trial flops - Fierce Biotech

Mirati Therapeutics stock ticks higher amid Nasdaq delisting for sale to Bristol-Myers - Seeking Alpha

Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC

European Commission Approves Adagrasib in KRAS G12C-Mutated NSCLC - Cancer Network

Jan. 10 Quick Takes: Coherus ends TIGIT deal with Junshi - BioCentury

HDAC Inhibitor Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the ... - GlobeNewswire

Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation

Mirati Therapeutics describes new GTPase KRAS and mutant inhibitors for cancer - BioWorld Online

Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation

FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras

Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B

Bristol Myers to buy RayzeBio for $4.1 billion in targeted cancer therapy push - CNBC

Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition (NASDAQ:MRTX) - Seeking Alpha

Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B

Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B - Yahoo Finance

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024 - Yahoo Finance

EnerSys To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Analyst Expectations For Mirati Therapeutics's Future

Sanofi licenses fourth NK cell engager from Innate Pharma - Pharmaceutical Technology

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Bristol Myers (BMY) Partners With SystImmune for Oncology Drug

Bristol Myers (BMY) Partners With SystImmune for Oncology Drug - Yahoo Finance

Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?

Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?

Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period (2019-2032) | DelveInsight - PR Newswire

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

MRTX-1257 enhances radiotherapy effect in preclinical setting - BioWorld Online

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for ... - PR Newswire

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations - Yahoo Finance

Mirati wins conditional UK approval for Krazati in NSCLC - Pharmaceutical Technology

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for ... - PR Newswire

MRTXに似た銘柄